Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7842]

FDA amends pembrolizumab’s gastric cancer indication

FDA amends pembrolizumab’s gastric cancer indication

PHOEBE trial results show patients with advanced HER2-positive BC live longer on pyrotinib

PHOEBE trial results show patients with advanced HER2-positive BC live longer on pyrotinib

FDA approves pembrolizumab with chemotherapy for biliary tract cancer

FDA approves pembrolizumab with chemotherapy for biliary tract cancer

FDA approves toripalimab-tpzi for nasopharyngeal carcinoma

FDA approves toripalimab-tpzi for nasopharyngeal carcinoma

Metixene breakthrough: A new hope emerges for metastatic brain cancer patients

Metixene breakthrough: A new hope emerges for metastatic brain cancer patients

ESMO 2O23: Major pathologic response to neoadjuvant pembrolizumab in advanced melanoma trial exceeds 50 percent

ESMO 2O23: Major pathologic response to neoadjuvant pembrolizumab in advanced melanoma trial exceeds 50 percent

FDA approves ivosidenib for myelodysplastic syndromes

FDA approves ivosidenib for myelodysplastic syndromes

Anti-anxiety drug may improve brain cancer survival chances

Anti-anxiety drug may improve brain cancer survival chances

Clinical trial of adjuvant therapy combination shows improved recurrence-free survival in liver cancer patients at high-risk of recurrence

Clinical trial of adjuvant therapy combination shows improved recurrence-free survival in liver cancer patients at...

ESMO 2023: Amivantamab plus chemo with or without lazertinib reduced risk of disease progression or death for EGFR-mutated NSCLC

ESMO 2023: Amivantamab plus chemo with or without lazertinib reduced risk of disease progression or death for EGFR...

More from ecancer